

Lessons from withdrawn accelerated approvals in oncology

In the format provided by the
authors and unedited

Supplementary Note:

Additional General Notes

1. Beaver, J. A. & Pazdur, R. “Dangling” accelerated approvals in oncology. *N Engl J Med* 384, e68 (2021).
2. Parikh, R. B. *et al.* Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration Accelerated Approval. *JAMA Oncol.* 9, 567-569 (2023).
3. European Medicines Agency. *Conditional Marketing Authorisation*, <https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation>
4. U.S Food & Drug Administration. *Verified Clinical Benefit | Cancer Accelerated Approvals*, <https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals> (2022).
5. U.S Food & Drug Administration. *Withdrawn | Cancer Accelerated Approvals*, <https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals> (2022).
6. Judson, I. *et al.* Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *Lancet Oncol.* 15, 415-423 (2014).
7. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. *Report on the Deliberation Results - Istodax Injection*, <https://www.pmda.go.jp/files/000233298.pdf>
8. Wayant, C., Mohyuddin, G. R. & Prasad, V. The accelerated approval pathway in oncology: Balancing the benefits and potential harms. (2022).
9. Stein, W. D. *et al.* Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. *The Oncologist* 13, 1046-1054 (2008).
10. Gill, J. & Prasad, V. A reality check of the accelerated approval of immune-checkpoint inhibitors. *Nat. Rev. Clin. Oncol.* 16, 656-658 (2019).
11. Gyawali, B., Rome, B. N. & Kesselheim, A. S. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. *BMJ* 374 (2021).
12. Fojo, T. & Simon, R. M. Inappropriate censoring in Kaplan-Meier analyses. *Lancet Oncol.* 22, 1358-1360 (2021)

Approval and Confirmatory Trial Notes:

1. Fowler, N. H. *et al.* Umbralisib, a dual PI3K δ /CK1 ϵ inhibitor in patients with relapsed or refractory indolent lymphoma. *J. Clin. Oncol.* **39**, 1609 (2021). **Approval trial for umbralisib in marginal zone and follicular Lymphoma.**
2. Gribben, J. G. *et al.* Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+ Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): results from the phase 3 Unity-CLL study. *Blood* **136**, 37-39 (2020). **Confirmatory trial for umbralisib in marginal zone and follicular Lymphoma.**
3. U.S Food & Drug Administration. *FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma*, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-umbralisib-marginal-zone-lymphoma-and-follicular-lymphoma> (2021). **Initial FDA announcement for umbralisib in marginal zone and follicular lymphoma.**
4. Chung, H. C. *et al.* Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J. Thorac. Oncol.* **15**, 618-627 (2020). **Approval trial for pembrolizumab in metastatic small-cell lung cancer.**
5. Rudin, C. M. *et al.* Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. *J. Clin. Oncol.* **38**, 2369 (2020). **Confirmatory trial for pembrolizumab in metastatic small-cell lung cancer.**
6. U.S Food & Drug Administration. *FDA approves pembrolizumab for metastatic small cell lung cancer*, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-metastatic-small-cell-lung-cancer> (2019). **Initial FDA announcement granting approval for pembrolizumab in metastatic small-cell lung cancer.**
7. Schmid, P. *et al.* Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med* **379**, 2108-2121 (2018). **Approval trial for atezolizumab in triple negative breast cancer.**
8. Miles, D. *et al.* Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann. Oncol.* **32**, 994-1004 (2021). **Confirmatory trial for atezolizumab in triple negative breast cancer.**
9. U.S Food & Drug Administration. *FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer*, <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative> (2019). **Initial FDA announcement granting accelerated approval for atezolizumab in triple negative breast cancer.**

10. Flinn, I. W. *et al.* The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. *Blood* **132**, 2446-2455 (2018). **Approval trial for duvelisib in chronic lymphocytic leukemia and small lymphocytic leukemia.**
11. Flinn, I. W. *et al.* DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. *J. Clin. Oncol.* **37**, 912-+ (2019). **Confirmatory trial for duvelisib in chronic lymphocytic leukemia and small lymphocytic leukemia.**
12. U.S Food & Drug Administration. *Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)*, <https://www.fda.gov/drugs/resources-information-approved-drugs/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lymphocytic-leukemia> (2018). **Initial FDA announcement granting approval for duvelisib in chronic lymphocytic leukemia and small lymphocytic leukemia.**
13. Antonia, S. J. *et al.* Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol.* **17**, 883-895 (2016). **Approval trial for nivolumab in small-cell lung cancer.**
14. Owonikoko, T. K. *et al.* Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. *J. Clin. Oncol.* **39**, 1349 (2021). **Confirmatory trial for nivolumab in small-cell lung cancer.**
15. U.S Food & Drug Administration. *FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer*, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-third-line-treatment-metastatic-small-cell-lung-cancer> (2018). **Initial FDA announcement granting approval for Nivolumab in metastatic small cell lung cancer.**
16. Fuchs, C. S. *et al.* Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol.* **4**, e180013-e180013 (2018). **Approval trial for pembrolizumab in gastric and gastroesophageal junction cancer.**
17. Shitara, K. *et al.* Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* **392**, 123-133 (2018). **Confirmatory trial for pembrolizumab in gastric and gastroesophageal junction cancer.**
18. U.S Food & Drug Administration. *FDA grants accelerated approval to pembrolizumab for advanced gastric cancer*, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-advanced-gastric-cancer> (2017). **Initial FDA announcement granting accelerate approval for pembrolizumab in gastric and gastroesophageal junction cancer.**
19. El-Khoueiry, A. B. *et al.* Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* **389**, 2492-2502 (2017). **Approval trial for nivolumab in hepatocellular carcinoma.**

20. Yau, T. *et al.* Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* **23**, 77-90 (2022). **Confirmatory trial for nivolumab in hepatocellular carcinoma.**
21. U.S Food & Drug Administration. *FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib*, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib> (2017). **Initial FDA announcement granting approval for nivolumab in hepatocellular carcinoma.**
22. Powles, T. *et al.* Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. *JAMA Oncol.* **3**, e172411-e172411 (2017). **Approval trial for durvalumab in urothelial carcinoma.**
23. Powles, T. *et al.* Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* **21**, 1574-1588 (2020). **Confirmatory trial for durvalumab in urothelial carcinoma.**
24. U.S Food & Drug Administration. *Durvalumab (Imfinzi)*, <https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi> (2017). **Initial FDA announcement granting approval for durvalumab in urothelial carcinoma.**
25. Tap, W. D. *et al.* Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. *Lancet* **388**, 488-497 (2016). **Approval trial for olaratumab in soft-tissue sarcoma.**
26. Tap, W. D. *et al.* Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. *JAMA* **323**, 1266-1276 (2020). **Confirmatory trial for olaratumab in soft-tissue sarcoma.**
27. U.S Food & Drug Administration. *FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma*, <https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-advanced-soft-tissue-sarcoma> (2019). **Initial FDA announcement granting accelerated approval for olaratumab in soft tissue sarcoma.**
28. Rosenberg, J. E. *et al.* Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* **387**, 1909-1920 (2016). **Approval trial for atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy.**
29. Powles, T. *et al.* Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* **391**, 748-757 (2018). **Confirmatory trial for atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy.**

30. U.S Food & Drug Administration. *Atezolizumab for Urothelial Carcinoma*, <https://www.fda.gov/drugs/resources-information-approved-drugs/atezolizumab-urothelial-carcinoma> (2016). **Initial FDA announcement granting accelerated approval for atezolizumab for urothelial carcinoma previously treated with platinum containing chemotherapy.**
31. Balar, A. V. *et al.* Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet* **389**, 67-76 (2017). **Approval trial for atezolizumab in urothelial carcinoma not eligible for platinum-containing chemotherapy.**
32. Galsky, M. D. *et al.* Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *The Lancet* **395**, 1547-1557 (2020). **Confirmatory trial for atezolizumab in urothelial carcinoma not eligible for platinum-containing chemotherapy.**
33. European Society of Medical Oncology. *FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Certain Patients with Advanced Bladder Cancer*, <https://www.esmo.org/oncology-news/archive/fda-grants-atezolizumab-accelerated-approval-as-initial-treatment-for-certain-patients-with-advanced-bladder-cancer> (2017). Report of **FDA announcement granting accelerated approval for atezolizumab for urothelial carcinoma ineligible for treatment with platinum containing chemotherapy.**
34. San-Miguel, J. F. *et al.* Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol.* **15**, 1195-1206 (2014). **Approval trial for panobinostat in multiple myeloma.**
35. U.S Food and Drug Administration. *Drug Trials Snapshot: FARYDAK (panobinostat)*, <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-farydak-panobinostat> (2015). **FDA summary of initial approval for panobinostat in multiple myeloma.**
36. Gopal, A. K. *et al.* PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med* **370**, 1008-1018 (2014). **Approval trial for idealisb in relapsed follicular B-cell Non-Hodgkin lymphoma.**
37. Cancer Network. *FDA Approves Idelalisib (Zydelig) for Three Types of Blood Cancer*, <https://www.cancernetwork.com/view/fda-approves-idelalisib-zydelig-three-types-blood-cancer> (2014). **Initial FDA announcement for idealisib in relapsed follicular B-cell Non-Hodgkin lymphoma.**
38. Schiller, G. *et al.* Vincristine sulfate liposomes injection (VSLI)“bridging” to potentially curative hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). *J. Clin. Oncol.* **29**, 6527-6527 (2011). **Approval trial for Vincristine in Philadelphia (PH) chromosome negative (-) acute lymphoblastic leukaemia.**
39. Cancer Network. *FDA Approves Liposomal Vincristine (Marqibo) for Rare Leukemia*, <https://www.cancernetwork.com/view/fda-approves-liposomal-vincristine-marqibo->

- rare-leukemia (2012). **Initial FDA announcement granting approval for vincristine in philadelphia chromosome negative acute lymphoblastic leukaemia.**
40. Coiffier, B. *et al.* Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. *J. Clin. Oncol.* **30**, 631-636 (2012). **Approval trial for romidepsin in peripheral t-cell lymphoma.**
 41. Piekarz, R. L. *et al.* Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. *Blood* **117**, 5827-5834 (2011). **Approval trial for romidepsin in peripheral t-cell lymphoma.**
 42. Bachy, E. *et al.* Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). *J. Clin. Oncol.* **40**, 242-251 (2022). **Confirmatory trial for romidepsin in peripheral t-cell lymphoma.**
 43. U.S Food & Drug Administration. *Romidepsin Accelerated Approval*, https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2011/022393s004ltr.pdf (2011). **Initial FDA announcement granting approval for romidepsin for peripheral t-cell lymphoma.**